Biomarker Panel for AECOPD Diagnosis via MRM-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are imprecise and lack a reliable blood-based biomarker, failing to account for the heterogeneity of exacerbation pathways, which hampers early and accurate diagnosis.
Innovation Solution
A panel of biomarkers identified through multiple reaction monitoring-mass spectrometry (MRM-MS) is used to differentiate AECOPD from stable or convalescent states by analyzing peptide and protein markers, providing a diagnostic score with high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a single biomarker (e.g., CRP) is used for diagnosis, then the diagnostic method is simple and inexpensive, but the diagnostic accuracy and ability to distinguish AECOPD from stable states is insufficient
Solution Approach 1:
The patent divides the diagnostic approach into multiple discrete biomarker components (18 specific proteins including CRP, alpha-1 antitrypsin, haptoglobin, ceruloplasmin, etc.) rather than relying on a single marker. Each biomarker provides specific information about different aspects of the exacerbation pathology, allowing for more precise diagnosis through their combined evaluation.
Solution Approach 2:
The patent creates a composite diagnostic signature by combining multiple biomarkers into an integrated diagnostic panel. This composite approach leverages the complementary information from each individual biomarker to achieve superior diagnostic accuracy compared to any single marker alone, effectively creating a 'diagnostic material' that is more informative than its individual components.
2Adaptability or versatility
If common inflammatory markers like CRP are used, then the diagnostic approach is straightforward, but it fails to account for the heterogeneity of AECOPD pathways (respiratory viruses, bacterial infection, air pollution, cardiac dysfunction)
Solution Approach 1:
The patent designs a biomarker panel with multi-functional capability to detect diverse AECOPD etiologies. The same panel of 18 biomarkers serves multiple diagnostic purposes: identifying inflammatory pathways, distinguishing infectious from non-infectious causes, detecting cardiac involvement, and differentiating exacerbation from stable states. This universal panel replaces the need for multiple separate diagnostic tests for different hypotheses.
Solution Approach 2:
The patent employs an excessive number of biomarkers (18 proteins) beyond the minimum single marker traditionally used, ensuring that all possible AECOPD pathways are captured. This excessive approach guarantees comprehensive coverage of heterogeneous etiologies, with the understanding that not all biomarkers will be equally elevated in every case, but the panel as a whole provides robust multi-pathway detection.
3Productivity
If shotgun proteomics is used to detect biomarker candidates, then the approach is unbiased and comprehensive, but it suffers from low-throughput efficiency, poor accuracy and suboptimal quantitation
Solution Approach 1:
The patent performs preliminary action by pre-selecting and validating a specific panel of 18 biomarkers that are most relevant to AECOPD diagnosis before implementing the diagnostic test. This pre-identification phase, conducted using unbiased shotgun proteomics, establishes a fixed set of targets that can then be efficiently and accurately measured using targeted MRM-MS, combining the benefits of unbiased discovery with efficient quantification.
Solution Approach 2:
The patent substitutes the mechanical shotgun proteomics approach (which has throughput and quantitation limitations) with a targeted MRM-MS system. This replacement maintains the ability to detect the predetermined biomarker panel while achieving superior throughput efficiency, measurement precision, and quantitation accuracy, effectively replacing a less efficient analytical mechanism with a more optimized one.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biomarker panel significantly distinguishes AECOPD from convalescent states, offering improved diagnostic accuracy and predictive value, with sensitivity and specificity optimized for clinical detection of AECOPD.
Implementation Method 1
Multiple reaction monitoring-mass spectrometry (MRM-MS) offers an inexpensive, high-throughput platform with the ability to quantify hundreds of targeted proteins based on precursor-product ion pairs
Data Source
AI summary
Described are compositions and methods for diagnosing acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Multiple reaction monitoring mass spectrometry (MRM-MS) was used to quantify the amount of protein biomarkers in plasma samples from human subjects. The amount of the biomarkers in the sample can distinguish AECOPD from a stable or convalescent state of COPD, or from a subject without COPD.